CASI — CASI Pharmaceuticals Balance Sheet
0.000.00%
- $31.76m
- $34.06m
- $28.54m
- 31
- 18
- 31
- 15
Annual balance sheet for CASI Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 20-F | 20-F | 20-F |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 66.4 | 48.6 | 49.9 | 18.8 | 16.1 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 4.64 | 9.8 | 13 | 10.1 | 15.3 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 74 | 62 | 73.4 | 59.3 | 39.6 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 10.8 | 21.8 | 13.2 | 11.6 | 11.4 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 128 | 138 | 96.2 | 75.3 | 53.7 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 7.98 | 13.2 | 17 | 16.7 | 36.5 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 46.2 | 53.8 | 51.7 | 51.1 | 51.8 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 81.5 | 84.5 | 44.6 | 24.2 | 1.85 |
Total Liabilities & Shareholders' Equity | 128 | 138 | 96.2 | 75.3 | 53.7 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |